Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Paracetamol regulation findings

This article was originally published in The Tan Sheet

Executive Summary

Researchers found little evidence to support a hypothesis that regulations limiting paracetamol (acetaminophen) package sizes resulted in fewer poisoning deaths. Findings from an observational study by Oliver W. Morgan, Department of Primary Care and Social Medicine, Imperial College, London, et al., published in the April PLOS Medicine contradict a 2004 British Medical Journal study. The BMJ study found U.K. legislation limiting the number of acetaminophen and aspirin tablets sold in retail transactions reduced the number of overdose deaths (1"The Tan Sheet" Nov. 8, 2004, p. 9). Morgan et al. say decreased paracetamol-poisoning mortality coincided with the regulation. However, fatal poisonings involving aspirin and antidepressants also dropped. "This raises the question whether the decline in paracetamol deaths was due to the regulations or was part of a wider trend," they say...

You may also be interested in...



Acetaminophen-Related Overdose Deaths Down In UK Due To Law – BMJ

Legislation in the UK limiting the package sizes for acetaminophen and aspirin has reduced the number of deaths from overdose since its enactment in 1998, a study in the Oct. 29 British Medical Journal says

News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR

This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.

Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups

Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100385

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel